Single nucleotide polymorphisms in treatment of polycystic ovary syndrome: a systematic review / Ritu Deswal, Smiti Nanda, Amita Suneja Dang
Abstract As 15–20% of reproductive aged females are suffering from polycystic ovary syndrome (PCOS), a large number of pharmacological preparations are frequently available in the market for the treatment of PCOS; however, they seem to be ineffective and cause undesirable side effects. This has emphasized the need to optimize dosage regimens for individualized treatment. The objective of this systematic review is to review single nucleotide polymorphisms (SNPs) associated with drugs used for the treatment of PCOS to understand pharmacogenetics variability of patients to drug response there by helping clinicians in designing tailored treatments and possibly reducing adverse drug reactions. A comprehensive electronic literature search was conducted to highlight some clinically relevant SNPs that act to influence PCOS and associated co-morbidities. A total of 16 studies were included in this review. These genetic variations can be used as a potential target for pharmacotherapy and pharmacogenetic clinical trials for better diagnosis, management, and treatment planning.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:51 |
|---|---|
| Enthalten in: |
Drug metabolism reviews - 51(2019), 4, Seite 612-622 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Deswal, Ritu [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Themen: |
Co-morbidities |
|---|
| Umfang: |
1 Online-Ressource (11 p) |
|---|
| doi: |
10.1080/03602532.2019.1667380 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
KFL011189339 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL011189339 | ||
| 003 | DE-627 | ||
| 005 | 20230720210159.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230714s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/03602532.2019.1667380 |2 doi | |
| 035 | |a (DE-627)KFL011189339 | ||
| 035 | |a (KFL)prod_LgpH_10.1080/03602532.2019.1667380 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Deswal, Ritu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Single nucleotide polymorphisms in treatment of polycystic ovary syndrome: a systematic review |c Ritu Deswal, Smiti Nanda, Amita Suneja Dang |
| 264 | 1 | |c 2019 | |
| 300 | |a 1 Online-Ressource (11 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract As 15–20% of reproductive aged females are suffering from polycystic ovary syndrome (PCOS), a large number of pharmacological preparations are frequently available in the market for the treatment of PCOS; however, they seem to be ineffective and cause undesirable side effects. This has emphasized the need to optimize dosage regimens for individualized treatment. The objective of this systematic review is to review single nucleotide polymorphisms (SNPs) associated with drugs used for the treatment of PCOS to understand pharmacogenetics variability of patients to drug response there by helping clinicians in designing tailored treatments and possibly reducing adverse drug reactions. A comprehensive electronic literature search was conducted to highlight some clinically relevant SNPs that act to influence PCOS and associated co-morbidities. A total of 16 studies were included in this review. These genetic variations can be used as a potential target for pharmacotherapy and pharmacogenetic clinical trials for better diagnosis, management, and treatment planning | ||
| 653 | |a Single nucleotide polymorphism | ||
| 653 | |a polycystic ovary syndrome | ||
| 653 | |a pharmacogenetics | ||
| 653 | |a treatment | ||
| 653 | |a co-morbidities | ||
| 653 | |a pharmacotherapy | ||
| 700 | 1 | |a Nanda, Smiti |e verfasserin |4 aut | |
| 700 | 1 | |a Dang, Amita Suneja |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug metabolism reviews |d Abingdon : Taylor & Francis Group, 1972 |g 51(2019), 4, Seite 612-622 |h Online-Ressource |w (DE-627)KFL000006025 |w (DE-600)2028205-9 |w (DE-576)27387960X |x 1097-9883 |7 nnns |
| 773 | 1 | 8 | |g volume:51 |g year:2019 |g number:4 |g pages:612-622 |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/tandf-ejournals-pharmazie/doi.org/10.1080/03602532.2019.1667380 |m X:KFL |x Resolving-System |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-TFE | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 935 | |i IMPORT_0628_prod_LgpH_02 | ||
| 951 | |a AR | ||
| 952 | |d 51 |j 2019 |e 4 |h 612-622 | ||